Obalon Therapeutics, Inc. to Present at UBS Global Healthcare Conference

SAN DIEGO, May 22, 2017 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Andy Rasdal, Chief Executive Officer of Obalon, and William Plovanic, Chief Financial Officer of Obalon, will present at the following investor conference:

• UBS Global Healthcare Conference
  Tuesday, May 23, 2017, Presentation at 1:00pm EST
  Grand Hyatt, New York, NY
  Webcast Available at:
  https://cc.talkpoint.com/ubsx001/052217a_as/?entity=88_Q55L3I5

Live audio webcasts of the presentation can be accessed through the link above. Replays of the webcasts will be available for 90 days following each presentation.

About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.

For Obalon Therapeutics, Inc.

Investor Contact:
William Plovanic
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
[email protected]

Media:
Megan Driscoll
EvolveMKD
Office: +1 646 517 4220
[email protected]